Abstract: Objective To investigate the clinical effect of scutellaria barbata kidney-tonifying compound on NSCLC stage Ⅲ～Ⅳ.Methods 50 cases in the trial group were treated with the compound of scutellaria barbata youguiyin,and 50 cases in the control group were treated with NP chemotherapy.Results The survival rate of 0.5,1,2,3 years in the trial group were 86%,76%,72% and 70% respectively,while were 92%,80%,68% and 64% respectively in the control group,and the difference between the two groups was not significant(P>0.05).3 years after treatment,the improve rate of life quality in the trial control was 66%,and in the control group was 36%(P<0.01).The late effect rate of tumor body in the trial group was 18%,and in the control group was 60%(P<0.01).The inhibitive rate of marrow in the trial group was 6 %,and in the control group was 48%(P<0.01).The ratio of CD+4/CD+8 in the trial group was 1.46±0.32,and in the control group was1.12±0.26(P<0.05).The activity of NK cell in the trial group was 28.6±6.12,and in the control group was 18.24±4.98(P<0.05).Conclusions Comparing to NP chemotherapy,the treatment of scutellaria barbata youguiyin compound has advantages on high life quality and low toxin side effect.

Key words: Scutellaria barbata kidney-tonifying compound, Lung cancer, Clinical effect